Anna Miles1, Marie Jardine2, Felicity Johnston2, Martin de Lisle2, Philippa Friary2, Jacqui Allen3. 1. The University of Auckland, New Zealand. Electronic address: a.miles@auckland.ac.nz. 2. The University of Auckland, New Zealand. 3. The University of Auckland, New Zealand; Waitemata District Health Board, Auckland, New Zealand.
Abstract
PURPOSE: Lee Silverman Voice Treatment (LSVT LOUD®) is an effective therapy for phonation in Parkinson's Disease (PD) but little is known about any additional spread of effects to swallowing and cough function. This pilot study examined the effect of LSVT LOUD on pharyngeal swallowing parameters and reflexive cough strength. METHODS: Twenty participants (14 men, 6 women; mean 68years, SD3.5) with PD referred for LSVT LOUD with complaints of voice deterioration were recruited. Mean duration of PD was 6yrs., SD 3. Self-reported Eating Assessment Tool-10 scores ranging from 0 to 25 (normal<3). Prior to LSVT LOUD, 1-week post- and 6-months post-treatment, participants undertook a videofluoroscopic study of swallowing and aerodynamic measures of involuntary cough. RESULTS: All participants completed the LSVT LOUD programme; 3 participants were lost to follow-up at 6-months. All participants made significant gains in average sound pressure level (dB SPL). Aspiration was not observed. Pharyngeal residue (p<0.05) and pharyngeal area at rest reduced (p<0.01) while maximal opening of pharyngoesophageal segment (PES) (p<0.05) and PES opening duration (p<0.05) significantly increased. There was a significant improvement in involuntary cough peak expiratory flow rate and peak expiratory flow rise time. All changes were maintained at 6-months. CONCLUSION: LSVT LOUD demonstrates additional spread effects on pharyngoesophageal deglutitive function and involuntary cough effectiveness in people with mild PD referred with voice complaints. Consequently, LSVT LOUD has potential to provide additional benefits for swallowing safety and efficiency in this patient group.
PURPOSE: Lee Silverman Voice Treatment (LSVT LOUD®) is an effective therapy for phonation in Parkinson's Disease (PD) but little is known about any additional spread of effects to swallowing and cough function. This pilot study examined the effect of LSVT LOUD on pharyngeal swallowing parameters and reflexive cough strength. METHODS: Twenty participants (14 men, 6 women; mean 68years, SD3.5) with PD referred for LSVT LOUD with complaints of voice deterioration were recruited. Mean duration of PD was 6yrs., SD 3. Self-reported Eating Assessment Tool-10 scores ranging from 0 to 25 (normal<3). Prior to LSVT LOUD, 1-week post- and 6-months post-treatment, participants undertook a videofluoroscopic study of swallowing and aerodynamic measures of involuntary cough. RESULTS: All participants completed the LSVT LOUD programme; 3 participants were lost to follow-up at 6-months. All participants made significant gains in average sound pressure level (dB SPL). Aspiration was not observed. Pharyngeal residue (p<0.05) and pharyngeal area at rest reduced (p<0.01) while maximal opening of pharyngoesophageal segment (PES) (p<0.05) and PES opening duration (p<0.05) significantly increased. There was a significant improvement in involuntary cough peak expiratory flow rate and peak expiratory flow rise time. All changes were maintained at 6-months. CONCLUSION: LSVT LOUD demonstrates additional spread effects on pharyngoesophageal deglutitive function and involuntary cough effectiveness in people with mild PD referred with voice complaints. Consequently, LSVT LOUD has potential to provide additional benefits for swallowing safety and efficiency in this patient group.
Authors: S Bonavita; L Lavorgna; G Abbadessa; F Brigo; M Clerico; S De Mercanti; F Trojsi; G Tedeschi Journal: J Neurol Date: 2021-05-20 Impact factor: 4.849
Authors: Erika S Levy; Gemma Moya-Galé; Young Hwa M Chang; Katherine Freeman; Karen Forrest; Mitchell F Brin; Lorraine A Ramig Journal: EClinicalMedicine Date: 2020-06-28
Authors: Lawren VandeVrede; Peter A Ljubenkov; Julio C Rojas; Ariane E Welch; Adam L Boxer Journal: Neurotherapeutics Date: 2020-10 Impact factor: 7.620
Authors: Brent Bluett; Alexander Y Pantelyat; Irene Litvan; Farwa Ali; Diana Apetauerova; Danny Bega; Lisa Bloom; James Bower; Adam L Boxer; Marian L Dale; Rohit Dhall; Antoine Duquette; Hubert H Fernandez; Jori E Fleisher; Murray Grossman; Michael Howell; Diana R Kerwin; Julie Leegwater-Kim; Christiane Lepage; Peter Alexander Ljubenkov; Martina Mancini; Nikolaus R McFarland; Paolo Moretti; Erica Myrick; Pritika Patel; Laura S Plummer; Federico Rodriguez-Porcel; Julio Rojas; Christos Sidiropoulos; Miriam Sklerov; Leonard L Sokol; Paul J Tuite; Lawren VandeVrede; Jennifer Wilhelm; Anne-Marie A Wills; Tao Xie; Lawrence I Golbe Journal: Front Neurol Date: 2021-07-01 Impact factor: 4.003